FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2055282253> ?p ?o ?g. }

• W2055282253 endingPage "82" @default.
• W2055282253 startingPage "82" @default.
• W2055282253 abstract "14 The superior immunosuppressive properties of tacrolimus, micro emulsion cyclosporine (neoralR), and mycophenolate mofetil (MMF 2 and 3 gram) have been demonstrated in several recent clinical trials involving solid organ transplants. In this prospective, randomized study, we compared tacrolimus/“low-dose” MMF (TMBIR) and neoralR /“low-dose” MMF (NMBIR) based immunosuppressive regimens after kidney transplantation. Fifty three consecutive adult recipients of renal transplant were randomized to receive either tacrolimus (0.08 mg/kg/bid) (n=27) or neoralR (4 mg/kg/bid)(n=26) orally, started pre-operatively and continued if allograft demonstrated no post-operative acute tubular necrosis(ATN). Cytolytic antibody therapy was allowed in case of post-operative ATN. Both groups received similar “low-dose” MMF (500 mg/bid) and steroid (2 mg/kg/day to taper off after 1 year). Switch from tacrolimus to neoralR or vice versa was allowed after refractory rejection or severe adverse events. Patients were followed for 1 year for patient and graft survival and incidence of acute rejection. Both groups (TMBIR vs. NMBIR) were equally matched with respect to: patient's age (46.5±2.6 vs. 46.8±2.4 yr.), donor's age (37.1±2.7 vs. 38.8±3.2 yr.), Male (52 vs. 69%), Caucasian (81 vs. 92%), causes of ESRD, months on dialysis(25.8±5.9 vs. 31.6±7.5), panel reactive antibody (9.6±4.1 vs. 9±5.1%), HLA mismatch, cold ischemia time (14.4±1.5 vs. 15±1.6 hours), and type of transplant (cadaver: 66.6 vs. 76%), respectively. 1 year patient survival rates were 88.9% for TMBIR and 100% for NMBIR (p=ns) and 1 year graft survival rates were 88.9% for TMBIR and 96.1 for NMBIR (p=ns). There was no significant difference in the incidence of biopsy confirmed acute rejection: 14.8% (4/27) TMBIR and 23% (6/26) NMBIR patients, of these, steroid resistant rejections requiring cytolytic antibody therapy were higher in NMBIR group [50% (3/6) vs. 25% (1/4) p=ns]. 3 patients crossed over from NMBIR to TMBIR for refractory rejections and 1 patient crossed over from TMBIR to NMBIR for new onset seizure. There were 4 episodes of CMV infections all in TMBIR. Other infections, hematologic, and electrolyte abnormalities, post-transplant diabetes (1 in each group), neurologic, muskulo-skeletal, and gastrointestinal adverse events were similar in both groups. One patient in NMBIR developed malignant melanoma. Overall, our data show that both tacrolimus and micro-emulsion cyclosporine(neoralR) in combination with “low-dose” mycophenolate mofetil provide effective and comparable immunosuppression and have similar adverse events in kidney transplant recipients. TMBIR was associated with higher episodes of CMV infections." @default.
• W2055282253 created "2016-06-24" @default.
• W2055282253 creator A5005083760 @default.
• W2055282253 creator A5013391557 @default.
• W2055282253 creator A5019038442 @default.
• W2055282253 creator A5039318967 @default.
• W2055282253 creator A5079598927 @default.
• W2055282253 creator A5084263158 @default.
• W2055282253 creator A5085564914 @default.
• W2055282253 date "1998-05-01" @default.
• W2055282253 modified "2023-09-25" @default.
• W2055282253 title "TACROLIMUS/“LOW-DOSE” MYCOPHENOLATE MOFETIL VS. MICRO-EMULSION CYCLOSPORINE/ “LOW-DOSE” MYCOPHENOLATE MOFETIL AFTER KIDNEY TRANSPLANTATION-1 YEAR FOLLOW-UP OF A PROSPECTIVE, RANDOMIZED CLINICAL TRIAL." @default.
• W2055282253 doi "https://doi.org/10.1097/00007890-199805131-00014" @default.
• W2055282253 hasPublicationYear "1998" @default.
• W2055282253 type Work @default.
• W2055282253 sameAs 2055282253 @default.
• W2055282253 citedByCount "2" @default.
• W2055282253 crossrefType "journal-article" @default.
• W2055282253 hasAuthorship W2055282253A5005083760 @default.
• W2055282253 hasAuthorship W2055282253A5013391557 @default.
• W2055282253 hasAuthorship W2055282253A5019038442 @default.
• W2055282253 hasAuthorship W2055282253A5039318967 @default.
• W2055282253 hasAuthorship W2055282253A5079598927 @default.
• W2055282253 hasAuthorship W2055282253A5084263158 @default.
• W2055282253 hasAuthorship W2055282253A5085564914 @default.
• W2055282253 hasBestOaLocation W20552822531 @default.
• W2055282253 hasConcept C126322002 @default.
• W2055282253 hasConcept C126894567 @default.
• W2055282253 hasConcept C141071460 @default.
• W2055282253 hasConcept C168563851 @default.
• W2055282253 hasConcept C197934379 @default.
• W2055282253 hasConcept C2777350860 @default.
• W2055282253 hasConcept C2778033501 @default.
• W2055282253 hasConcept C2778063415 @default.
• W2055282253 hasConcept C2779978075 @default.
• W2055282253 hasConcept C2780091579 @default.
• W2055282253 hasConcept C2780303639 @default.
• W2055282253 hasConcept C2909675724 @default.
• W2055282253 hasConcept C2909935303 @default.
• W2055282253 hasConcept C2911091166 @default.
• W2055282253 hasConcept C71924100 @default.
• W2055282253 hasConcept C90924648 @default.
• W2055282253 hasConceptScore W2055282253C126322002 @default.
• W2055282253 hasConceptScore W2055282253C126894567 @default.
• W2055282253 hasConceptScore W2055282253C141071460 @default.
• W2055282253 hasConceptScore W2055282253C168563851 @default.
• W2055282253 hasConceptScore W2055282253C197934379 @default.
• W2055282253 hasConceptScore W2055282253C2777350860 @default.
• W2055282253 hasConceptScore W2055282253C2778033501 @default.
• W2055282253 hasConceptScore W2055282253C2778063415 @default.
• W2055282253 hasConceptScore W2055282253C2779978075 @default.
• W2055282253 hasConceptScore W2055282253C2780091579 @default.
• W2055282253 hasConceptScore W2055282253C2780303639 @default.
• W2055282253 hasConceptScore W2055282253C2909675724 @default.
• W2055282253 hasConceptScore W2055282253C2909935303 @default.
• W2055282253 hasConceptScore W2055282253C2911091166 @default.
• W2055282253 hasConceptScore W2055282253C71924100 @default.
• W2055282253 hasConceptScore W2055282253C90924648 @default.
• W2055282253 hasIssue "Supplement" @default.
• W2055282253 hasLocation W20552822531 @default.
• W2055282253 hasLocation W20552822532 @default.
• W2055282253 hasOpenAccess W2055282253 @default.
• W2055282253 hasPrimaryLocation W20552822531 @default.
• W2055282253 hasRelatedWork W163443629 @default.
• W2055282253 hasRelatedWork W1968765419 @default.
• W2055282253 hasRelatedWork W2017281732 @default.
• W2055282253 hasRelatedWork W2042268211 @default.
• W2055282253 hasRelatedWork W2063513203 @default.
• W2055282253 hasRelatedWork W2080910822 @default.
• W2055282253 hasRelatedWork W2118272408 @default.
• W2055282253 hasRelatedWork W2314615787 @default.
• W2055282253 hasRelatedWork W2890859371 @default.
• W2055282253 hasRelatedWork W4229643107 @default.
• W2055282253 hasVolume "65" @default.
• W2055282253 isParatext "false" @default.
• W2055282253 isRetracted "false" @default.
• W2055282253 magId "2055282253" @default.
• W2055282253 workType "article" @default.